Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell cycle checkpoint

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    69 result(s) found for: Cell cycle checkpoint. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-002860-29 Sponsor Protocol Number: ONC-2019-002 Start Date*: 2019-12-12
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo).
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003914-15 Sponsor Protocol Number: ACT16525 Start Date*: 2020-07-21
    Sponsor Name:Sanofi-Aventis Research and Development
    Full Title: Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, non-squamous, non–small-cell lung cancer (...
    Medical condition: Non-small cell lung cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BG (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000502-29 Sponsor Protocol Number: WO41994 Start Date*: 2020-09-01
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERAB...
    Medical condition: Renal cell carcinoma (RCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038395 Renal carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038400 Renal carcinoma stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) GR (Completed) PL (Trial now transitioned) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000058-24 Sponsor Protocol Number: Connect&Go Start Date*: Information not available in EudraCT
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.
    Medical condition: Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003829-30 Sponsor Protocol Number: RBN-2397-21-002 Start Date*: 2022-02-03
    Sponsor Name:Ribon Therapeutics, Inc
    Full Title: A Phase 1b/2, multicenter, single arm study of RBN-2397 in combination with pembrolizumab in patients with Squamous Cell Carcinoma of the Lung (SCCL)
    Medical condition: Advanced/metastatic NSCLC of squamous cell histology
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004864 10085300 Squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000503-13 Sponsor Protocol Number: DS7300-127 Start Date*: 2022-10-14
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Open-label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects with Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
    Medical condition: Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003436-13 Sponsor Protocol Number: 105RC101 Start Date*: 2016-05-24
    Sponsor Name:TRACON Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Prematurely Ended) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-006804-34 Sponsor Protocol Number: CYP003 Start Date*: 2022-09-27
    Sponsor Name:Cytovation ASA
    Full Title: A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squam...
    Medical condition: Advanced or metastatic: -Head and Neck Squamous Cell Carcinoma (HNSCC); -Melanoma; -Triple-Negative Breast Cancer (TNBC);
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006430-39 Sponsor Protocol Number: BO43936 Start Date*: 2023-03-07
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED OPEN LABEL PHASE II STUDY OF IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    25.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10086821 Advanced renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004046-16 Sponsor Protocol Number: IMC-F106C-101 Start Date*: 2020-04-08
    Sponsor Name:Immunocore Ltd.
    Full Title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Pos...
    Medical condition: HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers. Study IMC-F106C-101 will enroll participants with advanced cancers, including unresectable or metastatic melanoma, ovarian ca...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025665 Malignant melanoma of skin stage unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046769 Uterine carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-005132-26 Sponsor Protocol Number: CA209-025 Start Date*: 2012-09-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther...
    Medical condition: Advanced or metastatic (medically or surgically unresectable) clear-cell Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) DE (Completed) IT (Completed) AT (Completed) HU (Completed) CZ (Completed) DK (Completed) ES (Completed) NO (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002013-20 Sponsor Protocol Number: ALKS4230-001 Start Date*: 2020-02-14
    Sponsor Name:Alkermes, Inc.
    Full Title: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2)
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Temporarily Halted) NL (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000914-12 Sponsor Protocol Number: GASOLINE Start Date*: 2020-06-12
    Sponsor Name:University of Cologne
    Full Title: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors
    Medical condition: • Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor) • Prostate carcino...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10011677 Cutaneous T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000987-31 Sponsor Protocol Number: 35RC17_8825_IMMUNO-MYELO Start Date*: 2021-04-23
    Sponsor Name:CHU Rennes
    Full Title: Immunomonitoring and multiple myeloma: impact of lenalidomide on immune checkpoint expression
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005015-13 Sponsor Protocol Number: C0947 Start Date*: 2018-05-18
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
    Medical condition: Locally advanced squamous cell carcinoma of the oral cavity
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041857 Squamous cell carcinoma of the oral cavity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-001750-42 Sponsor Protocol Number: CA209-214 Start Date*: 2014-11-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
    Medical condition: Advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    11.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Completed) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003118-42 Sponsor Protocol Number: D419EC00001 Start Date*: 2019-04-16
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patien...
    Medical condition: Advanced Solid Tumors and Hematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004129-22 Sponsor Protocol Number: CJDQ443A12101 Start Date*: 2021-02-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
    Medical condition: advanced solid tumors harboring the KRAS G12C mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004662-33 Sponsor Protocol Number: I3Y-MC-JPBK Start Date*: 2014-09-17
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 3 Study of LY2835219 plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed Afte...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) AT (Completed) GR (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001285-10 Sponsor Protocol Number: CA209-171 Start Date*: 2015-05-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at...
    Medical condition: Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) DE (Completed) FI (Completed) DK (Completed) PT (Completed) ES (Ongoing) AT (Completed) GB (GB - no longer in EU/EEA) IE (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 20:05:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA